The post YZi Labs commits fresh $100M to Hash Global as institutional push gains pace appeared on BitcoinEthereumNews.com. YZi Labs has committed $100 million toThe post YZi Labs commits fresh $100M to Hash Global as institutional push gains pace appeared on BitcoinEthereumNews.com. YZi Labs has committed $100 million to

YZi Labs commits fresh $100M to Hash Global as institutional push gains pace

For feedback or concerns regarding this content, please contact us at [email protected]

YZi Labs has committed $100 million to Hash Global’s BNB holdings fund, an instrument that is being promoted as providing regulatory clarity for institutional investors.

With more institutions looking to invest in and hold digital assets, the outlet formerly going by the name Binance Labs has amped up its support for Hash Global, providing secure access as well as the regulatory clarity that these institutions require. 

The smooth progression of the digital asset strategy contrasts sharply with the board-level drama that has stalled its $500 million commitment to CEA Industries. 

YZi Labs commits $100 million to Hash Global 

YZi Labs, the investment arm led by former Binance Labs head Ella Zhang, announced a fresh $100 million strategic commitment to Hash Global’s BNB Holdings Fund. 

The new Holdings Fund is specifically for institutional investors. According to official documentation, it is expected to provide the regulatory clarity and custody systems that banks and funds require to hold digital assets. 

Unlike Bitcoin, which institutions mostly hold through ETFs, or Ethereum, the BNB path is being marketed as “ecosystem co-building,” meaning that investors’ capital will be affected by the performance of the BNB Chain, which now handles over 5 million daily active users.

Ella Zhang stated that BNB provides an attractive yield, directing attention to an earlier version of the fund, which has already delivered a 32.5% return in its first few months of operation.

KK, the founder of Hash Global, described the $100 million deal as a structural alignment.

The BNB Chain 2026 Technical Roadmap is aiming for extreme performance. The network is currently being optimized to handle 20,000 transactions per second with sub-second finality. 

YZi Labs’ BNB treasury arrangement with CEA Industries stalls 

Cryptopolitan previously reported on YZi Labs’ leadership struggle with CEA Industries (NASDAQ: BNC). The initial plan was for CEA Industries to replicate the success of Strategy (formerly MicroStrategy) to become a publicly traded U.S. company that holds a massive treasury of BNB tokens. 

As of March 2026, CEA Industries already holds over 500,000 BNB, making it one of the largest corporate treasuries of the asset in the world. 

However, in February 2026, YZi Labs partner Alex Odagiu accused the CEA board of “malicious manipulation” for delaying the annual shareholder meeting for over 400 days. To protect their positions, the CEA board allegedly adopted a shareholder rights plan that has been described as a “poison pill” that triggers if any group tries to acquire more than 15% of the company.

SEC filings from March 2, 2026, show that Thomas Hans, a director at CEA, reported indirect ownership of millions of warrants. YZi Labs has filed a preliminary consent statement with the SEC to try and replace the board. 

True to the trend of giving conflicting accounts of events, the board is proposing to lower management fees paid to 10X Capital, the asset manager for the BNB treasury, claiming a secret arrangement with YZi Labs. YZi Labs, on the other hand, alleges that the proposal is the board’s way of trying to entrench itself. Reports suggest the board even considered deviating from its BNB strategy and purchasing other assets like Solana. 

BNB is trading close to $640 at the time of writing, down less than 1% in the last 24 hours and up over 7% over the last week.

Source: https://www.cryptopolitan.com/yzi-labs-commits-100m-to-hash-global/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09